Comparing the Effectiveness and Safety of Platelet-Rich Fibrin vs. Platelet-Rich Plasma Injections in Treating Alopecia Areata

Phase 4

Not yet recruiting

• Conditions: Alopecia areata, unspecified,

• Registration Number: CTRI/2025/05/086230
• Lead Sponsor: Dr RPGMC Tanda

Brief Summary

Alopecia Areata is a common autoimmune disease with non-scarring type of hair loss without any clinical inflammatory signs, most treatments require multiple sittings of treatment and multiple needle pricks, some of treatment can cause atrophy, recurrence rates are also high. In this study aim is to study the efficacy and safety of  platelet rich fibrin in the treatment of alopecia areata and to compare efficacy and safety of intralesional platelet rich fibrin vs intralesional platelet rich plasma in patients of alopecia areata.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2025-02-05
• Study Start: 2025-05-13

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Patients of AA between Age group 18 to 50 years.
• Diagnosed clinically with alopecia areata of scalp coming to skin opd.
• Patients willing to give consent for inclusion in study 4.
• Patients who have not taken medical treatment for AA in any form for the last 6 months.
• Control group includes age and sex matched individuals without history of AA 6.
• Platelet count more than 1.5 lac.

Exclusion Criteria

• Patients with alopecia other than alopecia areata.
• Patients with active infection at the local site.
• Patients having keloidal tendency.
• Patients with blood coagulopathies.
• Platelet count less than 1.5 lacs per µl.
• Patients who are immunosuppressed (HIV, malignancy, steroid or chemotherapy).
• Pregnancy or lactation 8.
• Patients not willing to give written informed consent.
• Patient on anticoagulation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Investigator assessment scale	Baseline, 2, 4, 6 months

Secondary Outcome Measures

Name	Time	Method
Trichoscopic Analysis	1 Size of alopecia patch using measuring tape
Patients self-assessment	Baseline, 2, 4, 6 months
Improvement assessment based on SALT score	Baseline, 2, 4, 6 months

Trial Locations

Locations (1)

Dr RPGMC Tanda; 🇮🇳 Kangra, HIMACHAL PRADESH, India

Dr RPGMC Tanda

🇮🇳Kangra, HIMACHAL PRADESH, India

Dr Deepak soan

Principal investigator

07737638288

deepsoan@gmail.com